Homing to nonlymphoid tissues is not necessary for effector Th1 cell differentiation.
The differentiation of naive T cells into effector Th1 cells is a complex process that may proceed in two steps, commitment and development. Initial TCR engagement and IFN-gamma signaling instruct the T cells to commit to the Th1 lineage, while subsequent IL-12 and potentially TCR signaling induces final differentiation into irreversible, Th1 effector cells. In agreement with a multistep process of Th1 cell differentiation, effector Th1 cell generation requires repeated TCR and cytokine signaling, thus raising the possibility that commitment and differentiation processes may occur in two distinct anatomical sites, the lymphoid organ and the site of infection, respectively. We tested this possibility using a model of skin sensitization that permits a direct analysis of Ag-specific T cells both within lymphoid organs and at the site of sensitization. We show in this study that Ag presentation in the skin does not induce further differentiation of skin-infiltrating T cells that are highly divided and fully differentiated effector cells. Thus, effector Th1 cell differentiation is completed within lymphoid organs. In addition, we examined the heterogeneity of CD4 T cell responses in vivo through the analysis of the expression, by activated T cells, of different selectins, including P-selectin ligand and CD62L known to define separable effector populations. We delineated, in lymph nodes, at least five distinct subpopulations of activated CD4 T cells with different phenotypes and recirculation properties. Collectively, these results show that the lymphoid environment orchestrates T cell activation to generate a repertoire of effector T cells with a diversity of effector functions.
Bajénoff
Marc
M
Centre d'Immunologie de Marseille-Luminy, Institut National de la Santé et de la Recherche Médicale, Université de la Méditerranée, Parc Scientifique de Luminy, Marseille, France.
Guerder
Sylvie
S
D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000473:pathology; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D002465:Cell Movement / Q000235:genetics / Q000276:immunology*; D002470:Cell Survival / Q000235:genetics / Q000276:immunology; D004431:Ear, External; D004487:Edema / Q000235:genetics / Q000276:immunology / Q000473:pathology; D006614:Hindlimb; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation / Q000235:genetics; D008221:Lymphoid Tissue / Q000166:cytology* / Q000276:immunology* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008822:Mice, Transgenic; D009113:Muramidase / Q000008:administration & dosage / Q000276:immunology; D009928:Organ Specificity / Q000235:genetics / Q000276:immunology; D012867:Skin / Q000166:cytology* / Q000276:immunology* / Q000473:pathology; D018417:Th1 Cells / Q000166:cytology* / Q000276:immunology* / Q000473:pathology
D000941:Antigens; C421864:hen egg lysozyme; D009113:Muramidase